Obesity as Risk Factor for Acute Coronary Disease in Al-Mosul City in Iraq: A Cross-Sectional Study
Obesitas sebagai Faktor Risiko Penyakit Koroner Akut di Kota Al-Mosul, Irak: Sebuah Studi Cross-Sectional
DOI:
https://doi.org/10.21070/ijhsm.v2i2.110Keywords:
Acute Coronary Syndrome, Obesity, Lipid profile, Cholesterol, Triglycerides, HDL, VLDL, LDLAbstract
Background: Acute coronary syndrome represents a group of cardiac disorders that mainly occur due to a sudden reduction of the blood supply of the heart. This occurs when an atherosclerotic plaque ruptures withing the coronary arteries. Several risk factors are associated with the occurrence of ACS that can be classified as modifiable and non-modifiable risk factors. Prevention of more heart damage and mitigating the unfortunate consequences are crucial. Aim of Study: This research aims to identify the possible associations between obesity, lipid profile, and the risk of experiencing ACS in a specific geographic region (Al-Mosul City, Iraq). Methodology: This cross-sectional study was performed in Mosul City, Iraq, in 2025, this study provided data from 50 participants who were chosen according to s strict criteria including individuals experiencing obesity at any age and sex, people with a history of cardiovascular diseases, inherited cardiac disorders, and metabolic abnormality status. Data collection was adhered to under the supervision of the medical professional. Data included demographic data, laboratory investigation, and clinical measurement of the weight and height. Analysis was performed using Jamovi 2.4.1.0. Results: This study provided significant data about the risk factors that are affecting obese individuals to the possibility of having ACS, elevated BMI, and dyslipidemia was observed among participants, which raises the suspicion of experiencing ACS in the future. Conclusion: Obesity and dyslipidemia represent a serious healthcare problem worldwide, They are significant contributors to ACS risk. This study aims to identify these risk factors in Mosul City, Iraq, and to prevent further complications.
Highlights:
- ACS is triggered by plaque rupture, with modifiable and non-modifiable risk factors.
- Investigate obesity, lipid profile, and ACS risk in Mosul, Iraq.
- Obesity and dyslipidemia significantly contribute to ACS risk, requiring preventive measures..
Keywords: Acute Coronary Syndrome, Obesity, Lipid profile, Cholesterol, Triglycerides, HDL, VLDL, LDL.
References
[1]. B. A. Bergmark, N. Mathenge, P. A. Merlini, M. B. Lawrence-Wright, and R. P. Giugliano, “Acute Coronary Syndromes,” The Lancet, vol. 399, no. 10332, pp. 1347–1358, Apr. 2022.
[2]. N. Makki, T. M. Brennan, and S. Girotra, “Acute Coronary Syndrome,” J. Intensive Care Med., vol. 30, no. 4, pp. 186–200, May 2015.
[3]. F. Sanchis-Gomar, C. Perez-Quilis, R. Leischik, and A. Lucia, “Epidemiology of Coronary Heart Disease and Acute Coronary Syndrome,” Ann. Transl. Med., vol. 4, no. 13, Jul. 2016.
[4]. A. Eisen, R. P. Giugliano, and E. Braunwald, “Updates on Acute Coronary Syndrome: A Review,” JAMA Cardiol., vol. 1, no. 6, pp. 718–730, Sep. 2016.
[5]. A. Rosengren et al., “Cardiovascular Risk Factors and Clinical Presentation in Acute Coronary Syndromes,” Heart, vol. 91, no. 9, pp. 1141–1147, Sep. 2005.
[6]. P. Yadav et al., “Clinical Profile & Risk Factors in Acute Coronary Syndrome,” Natl. J. Community Med., vol. 1, no. 2, pp. 150–152, Dec. 2010.
[7]. A. J. Mirza, A. Y. Taha, and B. R. Khdhir, “Risk Factors for Acute Coronary Syndrome in Patients Below the Age of 40 Years,” Egypt. Heart J., vol. 70, no. 4, pp. 233–235, Dec. 2018.
[8]. H. González-Pacheco et al., “Prevalence of Conventional Risk Factors and Lipid Profiles in Patients With Acute Coronary Syndrome and Significant Coronary Disease,” Ther. Clin. Risk Manag., vol. 10, pp. 815–823, Oct. 2014.
[9]. P. K. Shah, “New Insights Into the Pathogenesis and Prevention of Acute Coronary Syndromes,” Am. J. Cardiol., vol. 79, no. 12, pp. 17–23, Jun. 1997.
[10]. V. Fuster and J. C. Kovacic, “Acute Coronary Syndromes: Pathology, Diagnosis, Genetics, Prevention, and Treatment,” Circ. Res., vol. 114, no. 12, pp. 1847–1851, Jun. 2014.
[11]. J. Quiles and B. Miralles-Vicedo, “Secondary Prevention Strategies for Acute Coronary Syndrome,” Rev. Esp. Cardiol. (Engl. Ed.), vol. 67, no. 10, pp. 844–848, Oct. 2014.
[12]. H. Y. Lee, C. E. Cooke, and T. A. Robertson, “Use of Secondary Prevention Drug Therapy in Patients With Acute Coronary Syndrome After Hospital Discharge,” J. Manag. Care Pharm., vol. 14, no. 3, pp. 271–280, Apr. 2008.
[13]. M. Leoncini et al., “Early High-Dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome: Results From the PRATO-ACS Study,” J. Am. Coll. Cardiol., vol. 63, no. 1, pp. 71–79, Jan. 2014.
[14]. H. Daida et al., “Management and Two-Year Long-Term Clinical Outcome of Acute Coronary Syndrome in Japan—Prevention of Atherothrombotic Incidents Following Ischemic Coronary Attack (PACIFIC) Registry,” Circ. J., vol. 77, no. 4, pp. 934–943, 2013.
[15]. G. Gallone et al., “Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review,” J. Am. Coll. Cardiol., vol. 72, no. 23, pp. 2886–2903, Dec. 2018.
[16]. M. Piironen et al., “Trends in Long-Term Prognosis After Acute Coronary Syndrome,” Eur. J. Prev. Cardiol., vol. 24, no. 3, pp. 274–280, Feb. 2017.
[17]. A. Goldberg et al., “Coronary Dominance and Prognosis of Patients With Acute Coronary Syndrome,” Am. Heart J., vol. 154, no. 6, pp. 1116–1122, Dec. 2007.
[18]. F. Ye et al., “Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review,” Clin. Med. Res., vol. 17, no. 1–2, pp. 11–19, Jun. 2019.
[19]. P. G. Kopelman, “Obesity as a Medical Problem,” Nature, vol. 404, no. 6778, pp. 635–643, Apr. 2000.
[20]. C. J. Brewer and A. H. Balen, “Focus on Obesity,” Reproduction, vol. 140, no. 3, pp. 347–364, 2010.
[21]. Y. C. Chooi, C. Ding, and F. Magkos, “The Epidemiology of Obesity,” Metabolism, vol. 92, pp. 6–10, Mar. 2019.
[22]. G. A. Bray, “Medical Consequences of Obesity,” J. Clin. Endocrinol. Metab., vol. 89, no. 6, pp. 2583–2589, Jun. 2004.
[23]. X. Pi-Sunyer, “The Medical Risks of Obesity,” Postgrad. Med., vol. 121, no. 6, pp. 21–33, Nov. 2009.
[24]. P. B. Goldblatt, M. E. Moore, and A. J. Stunkard, “Social Factors in Obesity,” JAMA, vol. 192, no. 12, pp. 1039–1044, Jun. 1965.
[25]. M. Komaroff, “For Researchers on Obesity: Historical Review of Extra Body Weight Definitions,” J. Obes., vol. 2016, no. 1, p. 2460285, 2016.
[26]. J. A. Yanovski and S. Z. Yanovski, “Recent Advances in Basic Obesity Research,” JAMA, vol. 282, no. 16, pp. 1504–1506, Oct. 1999.
[27]. B. J. George et al., “Common Scientific and Statistical Errors in Obesity Research,” Obesity (Silver Spring), vol. 24, no. 4, pp. 781–790, Apr. 2016.
[28]. K. M. Gadde, C. K. Martin, H. R. Berthoud, and S. B. Heymsfield, “Obesity: Pathophysiology and Management,” J. Am. Coll. Cardiol., vol. 71, no. 1, pp. 69–84, Jan. 2018.
[29]. C. M. Salome, G. G. King, and N. Berend, “Physiology of Obesity and Effects on Lung Function,” J. Appl. Physiol., vol. 108, no. 1, pp. 206–211, Jan. 2010.
[30]. The Jamovi Project, Jamovi (Version 2.5) [Computer Software], 2024. Available: https://www.jamovi.org.
